Yiqi Fumai Lyophilized Injection(YQFM)

PreclinicalSmall molecule

CChina Academy of Chinese Medical Sciences

Yiqi Fumai Lyophilized Injection(YQFM) is one of 36 small molecule programs targeting Heart Failure. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Heart FailureActive, not recruiting

Chronic Heart FailureNot yet recruiting

Heart FailurePreclinical

Active, not recruiting

Chronic Heart FailurePreclinical

Not yet recruiting

Competition

Competitive Landscape

206 competitors in Heart Failure

#DrugCompanyPhaseTrials

Bayer Aspirin

Bayer

Preclinical

2 2

Brethine

Sanofi

Preclinical

1 3

Medrol

Pfizer

Preclinical

1 4

Amidate

Pfizer

Preclinical

1 5

Zemplar

Adriamycin

Savaysa

Activase

Xifaxan

2 10

Xylocaine

MMEDRx USA, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalNot yet recruiting

Chronic Heart Failure

NCT07803471

Clinical

Trials by Indication[1]

Heart Failure1 trial

Effectiveness of Yiqi Fumai Lyophilized Injection for Acute Heart Failure

Unknown status·CChina Academy of Chinese Medical Sciences··NCT05586048·1,200 enrolled

Chronic Heart Failure1 trial

A Dual-Perspective, Multi-Method Integrated Pharmacoeconomic Evaluation of Yiqi Fumai Lyophilized Injection for NYHA Class II or III Chronic Left Ventricular Dysfunction Due to Coronary Heart Disease in Patients With Qi and Yin Deficiency Syndrome: A Multicenter, Prospective, Open-Label, Single-Arm Performance-Goal Study

Not yet recruiting·CChina Academy of Chinese Medical Sciences·Preclinical·NCT07803471·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Yiqi Fumai Lyophilized Injection(YQFM). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Yiqi Fumai Lyophilized Injection(YQFM) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Yiqi Fumai Lyophilized Injection(YQFM). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — China Academy of Chinese Medical Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CChina Academy of Chinese Medical Sciences

Yiqi Fumai Lyophilized Injection(YQFM)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Heart Failure1 trial

Chronic Heart Failure1 trial

References

Drug Info

Quick Facts

Related News